Sugi Predict

Sugi Predict / Targets / HABP2

HABP2

Hyaluronan-binding protein 2 · Q14520 · HABP2 on Sugi Atlas →

8 patent compounds predicted against HABP2, 4 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29379316 SCHEMBL29379316 1.00 1/20
SCHEMBL87593 SCHEMBL87593 0.45 1/20
SCHEMBL88459 SCHEMBL88459 0.42 1/20
SCHEMBL4410143 SCHEMBL4410143 0.42 1/20

Clinical trials — most relevant to HABP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery PHASE4COMPLETED
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis PHASE4COMPLETED
rhuFVIIa in Post-partum Hemorrhage PHASE4COMPLETED
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） PHASE4RECRUITING
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor PHASE3UNKNOWN
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. PHASE3COMPLETED
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen PHASE3COMPLETED
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A PHASE3COMPLETED
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A PHASE3ACTIVE_NOT_RECRUITING
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa PHASE3COMPLETED
Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) PHASE2UNKNOWN
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors PHASE2UNKNOWN
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) PHASE2COMPLETED
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B PHASE2COMPLETED
Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State PHASE1COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Correlation Between PT and INR to Factor 7 nanUNKNOWN
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD) nanCOMPLETED
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital nanUNKNOWN
Inflammation Markers Over Time in Cardiovascular Disease nanCOMPLETED
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders nanRECRUITING
Heparin Management During Cardiopulmonary Bypass in Children nanCOMPLETED
Treatment of Inherited Factor VII Deficiency nanCOMPLETED
Are There Differences Between Carriers of Haemophilia A and B? nanCOMPLETED
Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders nanCOMPLETED
Observational Registry of the Treatment of Glanzmann's Thrombasthenia nanCOMPLETED
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury nanCOMPLETED
Improved Factor VIII Inhibitor Evaluation nanWITHDRAWN
Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital nanNOT_YET_RECRUITING
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a HABP2 binder may also engage these)

ProteinNameSimilarity
Q5E9Z2 — 1.000 Q5E9Z2 →
Q6L711 — 1.000 Q6L711 →
Q8K0D2 — 0.997 Q8K0D2 →
P18292 — 0.996 P18292 →
P04185 — 0.994 P04185 →
P49150 — 0.994 P49150 →
P11214 — 0.992 P11214 →
P29598 — 0.992 P29598 →
P19637 — 0.992 P19637 →
P19221 — 0.992 P19221 →
F10 Coagulation factor X 0.992 landscape →
Q5R537 — 0.991 Q5R537 →
Q8MHY7 — 0.991 Q8MHY7 →
P31394 — 0.990 P31394 →
Q5RF29 — 0.990 Q5RF29 →
Q8SQ23 — 0.990 Q8SQ23 →
P33587 — 0.990 P33587 →
PLAU Urokinase-type plasminogen activator 0.990 landscape →
Q08048 — 0.989 Q08048 →
P17945 — 0.989 P17945 →
Q58L93 — 0.989 Q58L93 →
HGF Hepatocyte growth factor 0.989 landscape →
Q5E9P5 — 0.989 Q5E9P5 →
P00743 — 0.989 P00743 →
P16227 — 0.989 P16227 →
Q4R577 — 0.989 Q4R577 →
P57727 — 0.988 P57727 →
Q1L659 — 0.988 Q1L659 →
P98119 — 0.988 P98119 →
P98121 — 0.988 P98121 →